Codex

The Bottom Line from the Web

The web evidence says Centene's problem was not just a bad quarter: the July 1, 2025 guidance withdrawal came from a large miss in Marketplace risk-adjustment assumptions, and the March-April 2026 news flow suggests the recovery plan now depends on repricing and tighter execution rather than renewed membership growth. The most important non-filing insight is that management appears willing to accept a steep ACA enrollment decline to restore margins, while analysts remain split and the company's older PBM and compliance overhangs are still not fully gone.

Average Analyst Target

$41.94

▲ 11.9% Upside vs. $37.48

2026 Adj. EPS Floor

3.00

2025 Risk-Adjustment Hit

$1,800,000,000

Short Interest / Float

2.97%

▲ 5.42% Peer average

What Matters Most

The core web finding is that Centene's 2025 miss was a Marketplace modeling failure, not a normal trim to guidance

On July 1, 2025, Centene withdrew its 2025 EPS guidance after Wakely data from 22 of its 29 Marketplace states, representing about 72% of Marketplace membership, implied a roughly $1.8 billion reduction in expected net risk-adjustment transfer revenue, or about $2.75 of adjusted EPS, with additional downside still possible in the remaining seven states. That is the single biggest web-disclosed event because it reframes 2025 as a breakdown in pricing and morbidity assumptions rather than a routine earnings reset. Sources: [Centene guidance withdrawal](https://investors.centene.com/2025-07-01-CENTENE-CORPORATION-WITHDRAWS-2025-GUIDANCE).

The 2026 repair plan appears to rely on margin over membership

S&P Global reported on March 20, 2026 that CEO Sarah London said ACA membership could shrink "somewhere between the high teens and the mid-30s" by year-end, with Centene prioritizing pricing and margin over raw enrollment. Combined with the February 6, 2026 guide for adjusted EPS above $3.00, the inference from the web is that earnings recovery is being engineered through repricing and tighter risk selection, not through broad-based growth in the exchange book. Sources: [S&P Global](https://www.spglobal.com/market-intelligence/en/news-insights/articles/2026/3/centene-shares-drop-as-leadership-predicts-drop-in-aca-membership-99873796), [2025 results and 2026 guidance](https://www.prnewswire.com/news-releases/centene-corporation-reports-2025-results-and-announces-2026-guidance-302680998.html).

April 2026 leadership changes look like an operating reset

Centene created two new group-president roles on April 6, 2026, hiring former Aetna/CVS executive Daniel Finke to run Medicaid and Commercial and expanding Michael Carson's remit across Medicare and Specialty. Inference: after the 2025 Marketplace shock, management is still redrawing accountability across the core businesses rather than signaling that the organization is already in a steady state. Source: [Centene leadership announcement](https://investors.centene.com/2026-04-06-Centene-Announces-New-Executive-Leadership-Structure).

Regulatory and legal cleanup is still incomplete

KFF Health News reported that Centene had reached PBM-related settlements with at least 20 states totaling more than $1 billion, but Georgia and Florida had still not publicly resolved their matters. Separate from that PBM overhang, DOJ said on February 18, 2025 that Centene and Health Net Federal Services agreed to pay $11.25 million to resolve alleged false cybersecurity certifications tied to TRICARE, while California's attorney general had already announced a $215.4 million PBM settlement in 2023. Sources: [KFF Health News](https://kffhealthnews.org/news/article/centene-settlements-pbms-medicaid-silence-holdouts-georgia-florida/), [DOJ](https://www.justice.gov/opa/pr/health-net-federal-services-llc-and-centene-corporation-agree-pay-over-11-million-resolve), [California AG](https://oag.ca.gov/news/press-releases/attorney-general-bonta-announces-215-million-settlement-against-healthcare).

Wall Street is cautious, not bullish

As of April 9, 2026, StockAnalysis showed a Hold consensus, a $41.94 average target versus a $37.48 share price, and a very wide $28 to $61 target range. March 2026 still brought cuts from Goldman Sachs to $32, JPMorgan to $41, and Mizuho to $41, even as Morgan Stanley raised its target to $45, which is another way of saying the Street sees a recovery case but not a settled one. Sources: StockAnalysis analyst forecast, MarketScreener Goldman update.

Late-2025 operating metrics do show real stabilization

The positive web signal is that Centene did stabilize after the July shock. The February 6, 2026 results release showed full-year 2025 adjusted EPS of $2.08, operating cash flow of $5.09 billion, and 2026 adjusted EPS guidance above $3.00, while Q4 Medicaid HBR improved to 93.0% after the Q3 release had already shown a 40-basis-point sequential improvement. Sources: [2025 results and 2026 guidance](https://www.prnewswire.com/news-releases/centene-corporation-reports-2025-results-and-announces-2026-guidance-302680998.html), [Q3 2025 results](https://investors.centene.com/2025-10-29-CENTENE-CORPORATION-REPORTS-THIRD-QUARTER-2025-RESULTS).

Insider trading turned supportive after the selloff, but the corpus does not show fresh 2026 buying

OpenInsider shows CEO Sarah London bought 19,230 shares on August 8, 2025 for about $490k and director Theodore Samuels II bought 9,000 shares on July 28, 2025 for about $249k. The latest filing in the supplied corpus is director Kenneth Burdick's December 3, 2025 sale after option exercise, so the web evidence is better than persistent selling but does not yet show visible 2026 insider accumulation. Source: [OpenInsider](http://openinsider.com/CNC).

Short interest is rising, but this is not a crowded short

Benzinga reported on February 23, 2026 that Centene had 12.73 million shares sold short, or 2.97% of float, up 4.21% from the prior report. That is meaningful skepticism, but it still sits below the cited peer average of 5.42%, which argues against a consensus bear pile-on. Source: Benzinga short interest.

Recent News Timeline

No Results

What the Specialists Asked

The supplied corpus did not include separate `proactive.json` or `insider-research.json` files, and `specialist-queries.json` was empty. This section therefore synthesizes the highest-value questions from the substantive specialist research files: `warren-research.json`, `quant-research.json`, `sherlock-research.json`, and `historian-research.json`.

Insider Spotlight

Sarah M. London has led Centene since 2022 after joining the company in 2020, and the web record shows the clearest insider conviction signal in the corpus: she bought 19,230 shares on August 8, 2025 for about $490k after the stock's 2025 collapse, on top of a smaller November 2024 purchase. That does not prove the turnaround, but it is more constructive than the absence of insider support would have been. Sources: Centene history, Potomac Officers Club background, OpenInsider.

Drew Asher, Centene's CFO, came from WellCare and Aetna/Coventry-related finance roles, and the web corpus shows a meaningful open-market buy of 17,200 shares on November 13, 2024 for about $1.0 million. That purchase still stands out because the corpus did not surface more recent executive buying in 2026. Sources: Potomac Officers Club background, OpenInsider.

Board signals are mixed rather than one-way bullish. Director Theodore Samuels II bought stock in July 2025, while director Kenneth Burdick's latest filing in the corpus is a December 2025 sale after option exercise; current-cycle compensation details were not surfaced in the supplied pages, although Centene's governance page links to a 2026 proxy statement. Sources: Centene board page, Centene governance page, OpenInsider.

No Results

Industry Context

Centene's web story is tightly tied to industry structure. The March 2026 S&P Global piece shows why Centene trades differently from peers: it has outsized ACA exchange exposure, so policy uncertainty and enrollment-mix changes hit it harder than larger diversified managed-care peers. Source: S&P Global.

PBM regulation is the second material industry theme. KFF Health News described rising scrutiny of PBMs from Congress and state officials even after Centene overhauled its PBM operations, which matters because unresolved state settlements keep old pricing practices relevant to the current valuation debate. Sources: KFF Health News, Cohen Milstein on Ohio.

The industry takeaway is that Centene is not just exposed to generic healthcare regulation. It is specifically exposed to ACA exchange repricing risk, Medicaid cost trend risk, and PBM reform risk, with each of those risks showing up directly in the recent web evidence.